大博医疗(002901) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥375,794,614.09, a decrease of 7.63% compared to ¥406,836,403.52 in the same period last year[22] - Net profit attributable to shareholders for Q3 2023 was ¥4,180,589.82, down 87.10% from ¥32,484,227.54 year-on-year[22] - The net profit after deducting non-recurring gains and losses was -¥11,675,344.11, a decline of 114.44% compared to ¥80,908,714.97 in the previous year[22] - The basic earnings per share for Q3 2023 was ¥0.0101, a decrease of 87.10% from ¥0.0785 in the same quarter last year[22] - The weighted average return on equity was 0.14%, down from 1.05% year-on-year[22] - Total operating revenue for Q3 2023 was CNY 1,125,437,608.63, a decrease of 8.8% compared to CNY 1,234,854,606.99 in Q3 2022[75] - The total operating profit for the period was approximately 135.59 million, a decrease from 266.88 million in the previous period, reflecting a decline of about 49.3%[76] - Net profit attributable to shareholders of the parent company was approximately 97.72 million, down from 212.55 million, representing a decrease of about 54.0%[76] - Basic and diluted earnings per share were both 0.2360, compared to 0.5174 in the previous period, indicating a decline of approximately 54.4%[77] - The total comprehensive income attributable to shareholders of the parent company was approximately 97.99 million, down from 209.76 million, a decrease of about 53.3%[77] - The total profit for the period was approximately 130.29 million, compared to 266.91 million in the previous period, reflecting a decrease of about 51.2%[76] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,937,639,963.01, an increase of 14.35% compared to the previous year[22] - The company's total assets increased by 14.36% to approximately ¥4.50 billion compared to the beginning of the year[41] - The total liabilities increased to CNY 1,292,962,047.72 in Q3 2023 from CNY 831,145,686.78 in Q3 2022, indicating a significant rise in financial obligations[67] - The company's total liabilities decreased, reflecting improved financial stability[64] - The total equity attributable to shareholders reached CNY 3,097,714,692.11 in Q3 2023, compared to CNY 2,999,717,260.36 in Q3 2022, showing growth in shareholder value[67] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥10,396,582.34, a decrease of 72.24% compared to ¥37,453,143.64 in the same period last year[22] - The net cash flow from operating activities for the current period is ¥10,396,582.34, a decrease of 72.8% compared to ¥37,453,143.64 in the previous period[46] - Total cash outflow from operating activities increased to ¥1,442,983,524.87, up from ¥1,416,856,874.94 in the previous period[46] - The company reported a significant decrease in cash received from investments, totaling ¥1,085,138,298.00, down 72.48% from ¥3,942,877,838.00 in the previous year[59] - Cash received from tax refunds increased by 170.34% to ¥3,994,230.02 from ¥1,477,502.46 in the same period last year[59] - Cash received from other operating activities rose by 31.45% to ¥126,137,587.25, compared to ¥95,959,618.08 in the previous year[59] - Cash and cash equivalents at the end of Q3 2023 stood at CNY 144,684,750.16, up from CNY 124,913,634.11 at the end of Q3 2022[72] - The company's cash and cash equivalents increased to ¥1,074,843,497.92 from ¥992,673,427.21 at the beginning of the year[64] Shareholder Information - The company reported a total of 24,576 common shareholders at the end of the reporting period[13] - Major shareholder Changzhou Dabo Tongshang Medical Investment Management Co., Ltd. holds 43.46% of the shares, while Dabo Medical International Investment Co., Ltd. holds 20.24%[13] Operational Costs and Expenses - The company's operating costs rose by 50.08% to approximately ¥368.27 million, primarily due to increased sales volume[33] - Total operating costs for Q3 2023 were CNY 1,046,739,500.28, slightly up from CNY 1,045,177,711.08 in the same period last year[75] - Research and development expenses increased to CNY 191,799,717.78 in Q3 2023 from CNY 186,012,065.32 in Q3 2022, reflecting a focus on innovation[75] - The company's investment income for Q3 2023 was CNY 6,606,030.21, down from CNY 13,405,734.02 in Q3 2022, reflecting challenges in investment performance[75] - The company’s income tax expenses decreased by 68.99% to approximately ¥12.82 million, corresponding to a decline in total profit[33] - The company’s income tax expense for the period was approximately 12.82 million, down from 41.34 million, a decrease of about 68.9%[76] Investments and Future Plans - The company plans to expand its market presence and invest in new technologies to enhance growth prospects[47] - The company’s construction in progress increased by 74.13% to approximately ¥196.95 million due to new project investments[33] - The company received government subsidies amounting to ¥20,053,798.43 during the current period, contributing to its non-operating income[56] Accounting Changes - The company implemented new accounting standards starting January 1, 2023, affecting the financial statements[80] - The deferred tax assets were adjusted to approximately 7.04 million after restatement, down from 7.17 million[81] - The deferred tax liabilities increased to approximately 5.01 million after restatement, up from 4.74 million[81]